midecamycin

Midecamycin is a 16-membered macrolide antibiotic originally isolated from the culture broth of Streptomyces mycarofaciens. It is used to treat a variety of infections caused by susceptible bacteria, including those in the oral cavity, upper and lower respiratory tracts, skin and soft tissues, as well as genitourinary tract infections. Its mechanism of action involves inhibiting bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby preventing peptide bond formation and translocation during protein synthesis. This results in inhibition of bacterial growth. It is effective against both erythromycin-susceptible and some erythromycin-resistant strains due to its activity against Gram-positive organisms and certain Gram-negative bacteria[1][2][4][5]. The drug has been marketed primarily in Japan (since 1974) and other countries such as Bulgaria and Slovenia but does not have current approval from US FDA or EMA[4].

Brand names

MacropenMyoxamNormicinaMosilMacro-Dil

Other names

midecamycin acetatemidecamycin diacetateMedecamycin A1Midecamycin A1Medemycin A1maidimeisuMidecaminmidekamycinmidekamycin acetatemydecamycinneoisomidecamycinPlatenomycin B1RubimycinEspinomycin ATurimycin P3MedemycinMomicineMadecacineMidecamicinaMidecamycineMidecamycinum